WORCESTER, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) — Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced the closing of its previously announced…Read More
Mustang Bio Announces Closing of 44 Million Registered Direct Offering Priced AttheMarket Under Nasdaq Rules
